#ESCCongress – [Abstract Only] Randomized trial: Low-dose edoxaban in very elderly patients with atrial fibrillation

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation – New England Journal of Medicine

Commentaries: Edoxaban Low-Dose for Elder Care Atrial Fibrillation – ELDERCARE-AF – American College of Cardiology AND ELDERCARE-AF: Edoxaban Superior to Placebo in Preventing Stroke, Systemic Embolism in Elderly Japanese AFib Patients – American College of Cardiology

Commentary on Twitter

Elderly patients with AF who were not candidates for standard doses of oral anticoagulants because of a high risk of bleeding were assigned to receive 15 mg of edoxaban or placebo once daily. Edoxaban was superior to placebo in preventing stroke or systemic embolism. #ESCCongress

— NEJM (@NEJM) August 30, 2020